<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 22, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02219477</url>
  </required_header>
  <id_info>
    <org_study_id>M14-227</org_study_id>
    <secondary_id>2014-001477-13</secondary_id>
    <nct_id>NCT02219477</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis</brief_title>
  <acronym>TURQUOISE-CPB</acronym>
  <official_title>An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis (TURQUOISE-CPB)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <authority>Germany: Ministry of Health</authority>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Canada: Health Canada</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and
      Dasabuvir with Ribavirin in Adults with Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir
      with Ribavirin in Adults with Genotype 4 Chronic Hepatitis C Virus Infection and
      Decompensated Cirrhosis.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of participants with Sustained Virologic Response 12 weeks post-treatment</measure>
    <time_frame>12 weeks after the last actual dose of study drug</time_frame>
    <safety_issue>No</safety_issue>
    <description>Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) less than the lower limit of quantification</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with virologic failure during treatment</measure>
    <time_frame>Up to 24 weeks while on treatment followed by 48 weeks after last actual dose of study drug</time_frame>
    <safety_issue>No</safety_issue>
    <description>The percentage of subjects with confirmed, quantifiable HCV RNA among subjects with previous unquantifiable HCV RNA during treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with virologic relapse post-treatment</measure>
    <time_frame>Up to 48 weeks after the last actual dose of study drug</time_frame>
    <safety_issue>No</safety_issue>
    <description>The percentage of subjects with confirmed, quantifiable HCV RNA among subjects with previous unquantifiable HCV RNA at the end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with improvement in laboratory parameters associated with hepatic function</measure>
    <time_frame>Up to Post-treatment Week 12</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>It will indicate improvement or worsening and percentage of subjects with improvement will be presented for each of the hepatic function laboratory parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Genotype 4 participants with Sustained Virologic Response 12 weeks post-treatment</measure>
    <time_frame>12 weeks after the last actual dose of study drug</time_frame>
    <safety_issue>No</safety_issue>
    <description>Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) less than the lower limit of quantification</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <condition>Decompensated Cirrhosis</condition>
  <condition>Hepatitis C Virus</condition>
  <arm_group>
    <arm_group_label>ABT-450/r/ABT-267 plus ABT-333 with RBV for 12 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-450/r/ABT-267 plus ABT-333 with ribavirin (RBV) for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABT-450/r/ABT-267 plus ABT-333 with RBV for 24 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-450/r/ABT-267 plus ABT-333 with ribavirin (RBV) for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABT-450/r/ABT-267 with RBV for 24 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-450/r/ABT-267 with ribavirin (RBV) for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-450/ritonavir/ABT-267</intervention_name>
    <description>tablet</description>
    <arm_group_label>ABT-450/r/ABT-267 plus ABT-333 with RBV for 12 weeks</arm_group_label>
    <arm_group_label>ABT-450/r/ABT-267 plus ABT-333 with RBV for 24 weeks</arm_group_label>
    <arm_group_label>ABT-450/r/ABT-267 with RBV for 24 weeks</arm_group_label>
    <other_name>ombitasvir/ABT-450/ritonavir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-333</intervention_name>
    <description>tablet</description>
    <arm_group_label>ABT-450/r/ABT-267 plus ABT-333 with RBV for 12 weeks</arm_group_label>
    <arm_group_label>ABT-450/r/ABT-267 plus ABT-333 with RBV for 24 weeks</arm_group_label>
    <arm_group_label>ABT-450/r/ABT-267 with RBV for 24 weeks</arm_group_label>
    <other_name>dasabuvir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>tablet</description>
    <arm_group_label>ABT-450/r/ABT-267 plus ABT-333 with RBV for 12 weeks</arm_group_label>
    <arm_group_label>ABT-450/r/ABT-267 plus ABT-333 with RBV for 24 weeks</arm_group_label>
    <arm_group_label>ABT-450/r/ABT-267 with RBV for 24 weeks</arm_group_label>
    <other_name>RBV</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. HCV Genotype 1(GT1)- or Genotype 4 (GT4)-infection defined as: Positive for anti-HCV
             Ab, HCV RNA &gt; 1,000 IU/mL and laboratory result indicating HCV GT1 infection at
             Screening.

          2. Evidence of cirrhosis by prior liver biopsy, FibroScan or by radiograph (i.e., CT or
             MRI).

          3. Child-Pugh Score 7 - 9 inclusive at time of Screening.

        Exclusion Criteria:

          1. Women who are pregnant or breastfeeding.

          2. Positive test result for Hepatitis B surface antigen (HbsAg) or anti-HIV antibodies
             (HIV Ab).

          3. Prior or current use of any other investigational or commercially available anti-HCV
             agents other than interferon/RBV and/or pegylated interferon (pegIFN)/RBV (including
             but not limited to telaprevir, boceprevir, sofosbuvir and simeprevir).

          4. Confirmed presence of hepatocellular carcinoma indicated on imaging techniques such
             as computed tomography (CT) scan or magnetic resonance imaging (MRI) within 3 months
             prior to Screening or on an ultrasound performed at Screening (a positive ultrasound
             result will be confirmed with CT scan or MRI).

          5. Any current or past evidence of Child-Pugh C classification.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Cohen, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 127578</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 127577</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 128358</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 127580</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 127582</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 127740</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 127626</name>
      <address>
        <city>Calgary</city>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 127628</name>
      <address>
        <city>Toronto</city>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 127627</name>
      <address>
        <city>Vancouver</city>
        <zip>V6Z-2K5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 127629</name>
      <address>
        <city>Vancouver</city>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 137264</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 127541</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 127542</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <lastchanged_date>October 16, 2015</lastchanged_date>
  <firstreceived_date>August 15, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C Genotype 1</keyword>
  <keyword>Chronic Hepatitis C</keyword>
  <keyword>Decompensated Cirrhosis</keyword>
  <keyword>Interferon-Free</keyword>
  <keyword>Hepatitis C</keyword>
  <keyword>Hepatitis C Virus</keyword>
  <keyword>Child-Pugh B</keyword>
  <keyword>Cirrhosis</keyword>
  <keyword>Hepatitis C Genotype 4</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Ritonavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
